These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22668524)

  • 1. Agomelatine treatment with adolescents with ADHD.
    Niederhofer H
    J Atten Disord; 2012 Aug; 16(6):530-2. PubMed ID: 22668524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating ADHD with agomelatine.
    Niederhofer H
    J Atten Disord; 2012 May; 16(4):346-8. PubMed ID: 22491963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial.
    Salardini E; Zeinoddini A; Kohi A; Mohammadi MR; Mohammadinejad P; Khiabany M; Shahriari M; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):513-9. PubMed ID: 27286139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
    Mac Avin M; Teeling M; Bennett KE
    BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of a new antidepressant : agomelatine].
    Mocaër E; Delalleau B; Boyer PA; de Bodinat C
    Med Sci (Paris); 2005 Oct; 21(10):888-93. PubMed ID: 16197911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on agomelatine.
    Green B
    Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Otasowie J; Castells X; Ehimare UP; Smith CH
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006997. PubMed ID: 25238582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
    Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
    J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
    Kennedy SH; Emsley R
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):93-100. PubMed ID: 16249073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.